Education
About Us
Working with TipRanks
Follow Us
Cybin, Inc. (CYBN)
:CYBN
CYBN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.50 - $17.83
Previous Close$9.5
Volume184.55K
Average Volume (3M)275.20K
Market Cap
$1.37M
Enterprise ValueN/A
Total Cash (Recent Filing)C$136.29M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Jun 25, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding21,026,426
10 Day Avg. Volume158,631
30 Day Avg. Volume275,196
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$70.75Price Target Upside867.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCYB003 has shown strong antidepressant effects in Phase II trials, with potential benefits lasting up to a year.
Market PotentialThere is a possibility for CYB003 to achieve blockbuster status by capturing a portion of Spravato's significant market share.
Regulatory AdvantageCYB003 has received Breakthrough Therapy Designation from the FDA, which might accelerate its path to potential approval.
Bears Say
Financial ConcernsHigher operating expenses than expected were driven by increased clinical trial activity, impacting financial models.
Potential DilutionPotential for dilution exists with most clinical-stage biopharma companies, including CYBN, due to ongoing trials and future capital requirements.
Price Target AdjustmentThere has been a moderate decrease in the price target for Cybin shares, reflecting updated estimates and competitive dynamics in the psychedelics space.
---
Ownership Overview
Currently, No data available
---
CYBN FAQ
What was Cybin, Inc.’s price range in the past 12 months?
Cybin, Inc. lowest stock price was $6.50 and its highest was $17.82 in the past 12 months.
What is Cybin, Inc.’s market cap?
Cybin, Inc.’s market cap is $1.37M.
When is Cybin, Inc.’s upcoming earnings report date?
Cybin, Inc.’s upcoming earnings report date is Jun 25, 2025 which is in 92 days.
How were Cybin, Inc.’s earnings last quarter?
Cybin, Inc. released its earnings results on Feb 11, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.732 by $0.363.
Is Cybin, Inc. overvalued?
According to Wall Street analysts Cybin, Inc.’s price is currently Undervalued.
Does Cybin, Inc. pay dividends?
Cybin, Inc. does not currently pay dividends.
What is Cybin, Inc.’s EPS estimate?
Cybin, Inc.’s EPS estimate is -0.85.
How many shares outstanding does Cybin, Inc. have?
Cybin, Inc. has 21,026,426 shares outstanding.
What happened to Cybin, Inc.’s price movement after its last earnings report?
Cybin, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.732. Following the earnings report the stock price went up 0.213%.
Which hedge fund is a major shareholder of Cybin, Inc.?
Currently, no hedge funds are holding shares in CYBN
---
Company Description
Cybin, Inc.
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
---
CYBN Stock 12 Month Forecast
Average Price Target
$70.75
▲(867.85% Upside)
Technical Analysis
Mydecine Innovations Group
―
Numinus Wellness
―
Red Light Holland
―
Entheon Biomedical
―
HAVN Life Sciences
―
Best Analysts Covering CYBN
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-31.54%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -31.54% per trade.
---